Laduviglusib (GMP)

Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.

Product Specifications

CAS Number

[252917-06-9]

Product Name Alternative

CHIR-99021 (GMP) ; CT99021 (GMP)

UNSPSC

12352005

Hazard Statement

H300, H312+H332, H315, H319, H335

Target

Autophagy; GSK-3; Wnt; β-catenin

Type

GMP Small Molecules

Related Pathways

Autophagy; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/laduviglusib-gmp.html

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N#CC1=CC=C(N=C1)NCCNC2=NC=C(C(C3=CC=C(Cl)C=C3Cl)=N2)C4=NC=C(N4)C

Molecular Formula

C22H18Cl2N8

Molecular Weight

465.34

Precautions

H300, H312+H332, H315, H319, H335

References & Citations

[1]Li X, et al. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. Cell Stem Cell. 2015;17 (2) :195-203. |[2]Guan J et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022;605 (7909) :325-331. |[3]Cao N, et al. Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science. 2016;352 (6290) :1216-1220. |[4]Choi IY, et al. Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Rep. 2016;15 (10) :2301-2312. |[5]Bar-Nur O, et al. Direct Reprogramming of Mouse Fibroblasts into Functional Skeletal Muscle Progenitors. Stem Cell Reports. 2018 May 8;10 (5) :1505-1521. |[6]Zhao J, et al. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat Med. 2022 Feb;28 (2) :272-282.